About half a billion people worldwide are living with genital herpes, and several billion have an oral herpes infection. Genital herpes is a substantial health concern worldwide, as reflected by the potential pain and discomfort suffered by people living with the infection and the associated social consequences that can profoundly affect sexual and reproductive health. Moreover, genital herps can significantly increase the risk of HIV infection. In US, nearly 600,000 new genital herpes infections in the United States in a single year. Nationwide, 11.9 % of persons aged 14 to 49 years have HSV-2 infection (12.1% when adjusted for age). Despite the severe health burden caused by this virus infection, no vaccine is available to prevent to treat HSV infection. The novel mRNA-based vaccine in this disclosure may provide a solution to deal with this virus infection.